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Abstract
This study compared the dosimetric performance of (a) volumetric modulated arc
therapy (VMAT) with standard optimization (STD) and (b) multi-criteria optimization
(MCO) to (c) intensity modulated radiation therapy (IMRT) with MCO for hippocam-
pal avoidance whole brain radiation therapy (HA-WBRT) in RayStation treatment
planning system (TPS). Ten HA-WBRT patients previously treated with MCO-IMRT
or MCO-VMAT on an Elekta Inﬁnity accelerator with Agility multileaf collimators
(5-mm leaves) were re-planned for the other two modalities. All patients received
30 Gy in 15 fractions to the planning target volume (PTV), namely, PTV30 expanded
with a 2-mm margin from the whole brain excluding hippocampus with margin. The
patients all had metastatic lesions (up to 12) of variable sizes and proximity to the
hippocampus, treated with an additional 7.5 Gy from a simultaneous integrated
boost (SIB) to PTV37.5. The IMRT plans used eight to eleven non-coplanar ﬁelds,
whereas the VMAT plans used two coplanar full arcs and a vertex half arc. The
averaged target coverage, dose to organs-at-risk (OARs) and monitor unit provided
by the three modalities were compared, and a Wilcoxon signed-rank test was per-
formed. MCO-VMAT provided statistically signiﬁcant reduction of D100 of hip-
pocampus compared to STD-VMAT, and Dmax of cochleas compared to MCO-
IMRT. With statistical signiﬁcance, MCO-VMAT improved V30 of PTV30 by 14.2%
and 4.8%, respectively, compared to MCO-IMRT and STD-VMAT. It also raised D95
of PTV37.5 by 0.4 Gy compared to both MCO-IMRT and STD-VMAT. Improved
plan quality parameters such as a decrease in overall plan Dmax and total monitor
units (MU) were also observed for MCO-VMAT. MCO-VMAT is found to be the
optimal modality for HA-WBRT in terms of PTV coverage, OAR sparing and delivery
efﬁciency, compared to MCO-IMRT or STD-VMAT.
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1 | INTRODUCTION
Brain metastases are an important source of morbidity for cancer
patients. Whole brain radiation therapy (WBRT) is effective, but
results in signiﬁcant neurocognitive side effects for many patients,
especially in terms of verbal memory. As survival for patients with
metastatic brain disease increases,1,2 approaches to spare neurocogni-
tion have become an intense area of study. Focal radiation with
stereotactic radiosurgery (SRS) is one approach that results in less
neurocognitive impairment,3 but is not an option for many patients
with more diffuse metastatic disease. One alternative that has gained
popularity in the last several years has been hippocampal avoidance
whole brain radiation therapy (HA-WBRT), which uses advanced radi-
ation techniques to reduce the dose to the hippocampus, an area
important for memory formation and neurogenesis.4 The RTOG 0933
phase II study showed evidence of improvements in quality of life and
memory preservation compared to historical WBRT controls.4 Hop-
kins Verbal Learning Test-Revised Delayed Recall (HVLT-R) revealed a
30% mean relative decline in WBRT without hippocampal avoidance
(baseline 4 months) versus 7% utilizing HA-WBRT along with no
decline in Quality of Life scores (QOL).4
Intensity modulated radiation therapy (IMRT) has been used as a
practical delivery method for HA-WBRT based on RTOG 0933
guidelines.5 Dose painting to metastatic lesions, although not
required by the RTOG protocol, has also been examined.6 Despite
these efforts, recent survey results from Slade et al.7 indicated 56%
of radiation oncologists (n = 196) would not consider (IMRT) for HA-
WBRT; among several factors was the complexity of the treatment
planning process which requires substantial training. More recently,
volumetric modulated arc therapy (VMAT) has also been examined
for HA-WBRT.8 VMAT showed superior dosimetric performance to
IMRT,9,10 and can practically deliver dose painting in form of simulta-
neous integrated boost (SIB)11 to multiple brain metastases,12,13
along with HA-WBRT.14,15
Dosimetric quality and efﬁciency for IMRT and VMAT were fur-
ther promoted by a recent advancement in inverse planning tech-
nology: multi-criteria optimization (MCO).16–21 MCO generates a
Pareto surface containing a spectrum of optimal plans, with every
point on the surface representing an optimal solution with different
trade-off objectives.16 A user is able to navigate combinations in
real-time based on speciﬁed trade-off objectives along with plan-
ning constraints.16 Numerous studies have conﬁrmed that MCO
improved plan quality over conventional inverse planning meth-
ods.17–21 In addition, MCO also reduced planning time and allowed
less-experienced treatment planners to efﬁciently produce high-
quality IMRT plans for complex targets in the close vicinity of
numerous organs-at-risk (OARs), such as tumors in the head and
neck region.20
The study aimed to compare three treatment planning methods –
IMRT with MCO (MCO-IMRT), VMAT with standard optimization
(STD-VMAT) and VMAT with MCO (MCO-VMAT), for HA-WBRT on
complex targets with a variety of conditions (0–12 metastatic lesions
with variable lesion sizes and different proximity to the hippocampus).
The effectiveness of using SIB to deliver the extra dose to the meta-
static lesions was also assessed for all three methods.
2 | MATERIALS AND METHODS
2.A | Patient selection
Ten patients previously treated with HA-WBRT using MCO-IMRT
(eight patients in RayStation v4.0) or MCO-VMAT (two patients in
RayStation 5.0) were anonymized and re-planned with STD-VMAT
and the other MCO modality — MCO-VMAT in RayStation v4.7 for
the eight patients originally receiving MCO-IMRT, and MCO-IMRT
RayStation v5.0 for the two patients treated by MCO-VMAT. The
vendor (RaySearch Laboratories, Stockholm, Sweden) has not chan-
ged the IMRT optimization algorithm since RayStation v4.0, and
VMAT since v4.7, which has been validated by our institutional
experiences. Therefore, it was not necessary to re-optimize all plans
in the latest version.
2.B | Computed tomography simulation
Computed tomography (CT) data were originally prepared based on the
RTOG 0933 criteria. All patients had MRI with axial T2-weighted and
gadolinium contrast-enhanced T1-weighted sequences for hippocam-
pus contouring with slice thickness no greater than 1.5 mm. They were
immobilized in the supine position with a thermoplastic mask for a CT
simulation with slice thickness of 1.25 mm with intravenous contrast.
The MRI images were semi-automatically fused to the simulation CT by
an attending radiation oncologist in MIM Vista version 6 (MIM Software
Inc., Cleveland, OH). Target structures (such as whole brain and distin-
guishable metastatic lesions), organs-at-risk (OARs) and external patient
contour w/immobilization devices were also contoured within MIM
before exporting to the treatment planning system (TPS). The hip-
pocampus was contoured based on the RTOG contouring guidelines.
The hippocampal avoidance region was generated by a 5 mm contour
expansion followed by a secondary 5 mm expansion to control the dose
gradient in the avoidance region. There were up to two levels of plan-
ning target volume (PTV). The hippocampal sparing whole brain PTV
included the whole brain parenchyma to C1 or C2 as the clinical target
volume (CTV) plus 2 mm expansion with subtraction of the hippocam-
pal avoidance regions. The metastatic PTV was expanded from the
delineated metastatic lesions with a 2 mm expansion.
2.C | Treatment prescription
Ten patients received 30 Gy in 15 fractions to the hippocampal
sparing whole brain PTV (PTV30) with an SIB of 37.5 Gy to speciﬁc
metastatic PTV (PTV37.5).
2.D | Custom optimization contours
All plans were given custom contours to guide the optimization pro-
cess. These contours included PTV30PTV37.5, a volume used to
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help improve dose uniformity within the whole brain region without
metastatic disease. A custom target structure was created within
PTV30 in between the left and right hippocampus for added control
of midline target coverage. A custom avoidance structure was
created inferior to the PTV30 to control excessive inferior dose to
uninvolved optic regions and oral cavity.
2.E | Treatment plan parameters
MCO-IMRT plans utilized a step-and-shoot delivery method (SMLC)
with eight to eleven beams at variable gantry angles (including one
to three non-coplanar angles) depending on the location of the
metastatic disease. All plans were optimized using a 6-MV photon
beam on an Elekta Inﬁnity linear accelerator employing Agility multi-
leaf collimator (MLC, 80 pairs of 5-mm leaves).
All VMAT plans were generated using dual coplanar full arcs
(clockwise/counterclockwise of 358°, between 181° and 179°), with
a ﬁxed collimator angle (between 20° to 40°) selected based on the
angle of hippocampus. A third non-planar vertex arc swept from 1°
to 179° with a 270° couch kick. All three arcs employed a control
point every 2° of gantry rotation. The dose grid resolution for all
plans was set to 0.2 9 0.25 9 0.2 cm3 (left-right, superior-inferior,
and anterior-posterior, respectively).
The use of multiple arcs has been shown to yield superior plan
quality.22 Furthermore, with the dual arc feature enabled, only one
set of ﬂuence proﬁles are optimized while more information from
the ﬂuence maps can be kept during the leaf sequencing process.
This ‘one arc’ ﬂuence map conserves leaf motion with one arc focus-
ing on the left side of the target and the second arc on the right side
at a given control point angle, which in turn reduces the leaf open-
ings over the OAR and increases sparing.23 Chen et al. reported that
the use of dual arcs in VMAT resulted in notable dosimetric
improvements for complex targets such as head and neck.24
The differences between the STD-VMAT (a.k.a., rayArc) and
MCO-VMAT optimization in RayStation were explained by Ghandour
et al.25 The rayArc uses a direct machine parameter optimization
(DMPO) algorithm that starts with a coarse arc segmentation (24°
spacing), while converting to optimized ﬂuence maps per initial angle.
The maps are then converted into a user determined 2–4 control
points per initial angle, while ﬁltering out the smallest points based on
a sorting algorithm.23 Control points are then converted to comply
with machine parameter motion constraints (e.g., max leaf speed, valid
dose rates, delivery time, number of monitor units per degree) along
with leaf/jaw positioning (static or dynamic). Chen et al. reported the
use of small arc spacing of 2° per control point led to notable dosimet-
ric improvements for complex targets such as head and neck.24
MCO empowers the user to produce a ﬁnal plan by considering
multiple criteria via the generation of a Pareto database followed by
a navigation process which smoothly interpolates amongst the plans
in the database. For a Pareto optimal plan, no criterion can be further
improved without sacriﬁcing another criterion. For photon optimiza-
tion in RayStation, for a plan with n objectives deﬁned, a minimum of
2n Pareto plans are needed to produce a practical approximation of
the Pareto surface,18 whereas the use of 4n plans leads to a closer
approximation to the true Pareto surface, which we use at our insti-
tute.19 In addition to objectives, constraints are used to focus on clin-
ically useful plans, creating a Pareto surface with smaller range but
ﬁner resolution. At least two constraints — the minimum dose for a
target and the maximum dose for an organ, are required to start the
Pareto plan generation. An MCO plan is selected by navigating on
the Pareto surface using the navigational sliders. A particular slider
can be clamped to limit the range of navigation on the Pareto surface
to prevent degradation while navigating other sliders in desired direc-
tions. Once navigated, the ﬂuence pattern of the selected Pareto
optimal plan is converted to deliverable machine parameters for each
control point using a ﬁnal dose calculation. In RayStation, this ﬁnal
deliverable plan is used for clinical evaluation.
MCO-VMAT uses three unique algorithms: a convex Pareto sur-
face approximation for ﬂuence maps, a ﬂuence map optimization for
the discrete Pareto surface representation (navigational best plan)
and DMPO VMAT optimization to generate MLC segments.25 Both
VMAT optimization techniques used a single-value pencil beam ker-
nel decomposition for approximation to save computational time. An
intermediate dose is used to minimize discrepancies between pencil
beam and collapsed cone algorithm (which is used in ﬁnal dose
calculation).25
2.F | Dosimetric and plan quality comparison
analysis
2.F.1 | Organs-at-risk
With regards to hippocampal sparing, four metrics were assessed to
determine plan quality: dose covering 100% volume (D100), mean
dose (Dmean), point max of hippocampus (Dmax) and percent vol-
ume receiving 10 Gy (V10). Combined lens dose and cochlea dose
(left and right) are assessed by point max (Dmax).
2.F.2 | Target coverage
The coverage of PTV30 was assessed by percentage of volume
receiving 25 Gy (V25) and 30 Gy (V30), whereas the coverage of
PTV37.5 and GTV37.5 was evaluated using dose covering 95%
(D95) and 99% (D99) of the volume, respectively.
2.F.3 | Plan quality parameters
Total monitor units and Dmax (Gy) for each plan was recorded. Dose
uniformity with control of the dose falloff was assessed using the
volume of PTV30PTV37.5. The V35 of PTV30 was also recorded
to determine the control of dose beyond 30 Gy in the whole brain
regions without metastatic disease.
2.F.4 | Statistical analysis
Statistical analysis was performed with a Wilcoxon signed-rank test
to determine if there was any signiﬁcant difference of the
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parameters examined along with standard deviations (SD). A P value
smaller than 0.05 was considered statistically signiﬁcant. The com-
parison was conducted between MCO-VMAT and MCO-IMRT, as
well as between MCO-VMAT and STD-VMAT. STD-VMAT was not
compared to MCO-IMRT.
3 | RESULTS
Table 1 shows the total plan MU, dose to OARs, maximum plan
dose, and target coverage for the ten patients. The number of meta-
static lesions, the size of the PTV and their proximity to the hip-
pocampus are also shown along with the coverage of the metastatic
PTV (PTV37.5). The results are shown for MCO-VMAT (MV), MCO-
IMRT (MI), and STD-VMAT (SV).
Table 2 shows the cumulative averages of the metrics illustrated
in Table 1 for each treatment modality. The results for the MCO-
VMAT are compared to MCO-IMRT and STD-VMAT separately, to
demonstrate any improvements resulted in by the use of MCO and
VMAT, respectively.
3.A | OAR sparing
As shown in Table 2, the cumulative averages of D100 and Dmean
for hippocampus were both lower for MCO-VMAT compared to
STD-VMAT or MCO-IMRT. Dmax to hippocampus was similar in all
three modalities. Decrease in hippocampus D100 using MCO-VMAT
was statistically signiﬁcant when compared to STD-VMAT. Cumula-
tive averages of the maximum dose to the lenses and that to the
cochleas were lower for MCO-VMAT, when compared to either
STD-VMAT or MCO-IMRT.
3.B | Target coverage
As shown in Table 2, MCO-VMAT achieved statistically signiﬁcant
improvement on prescription coverage for PTV30 when compared
to either MCO-IMRT or STD-VMAT, while maintaining lower OAR
values. The standard deviation of the V30 is also smaller for MCO-
VMAT, implying improved uniformity of plan quality. The use of
VMAT instead of IMRT in MCO planning resulted in an improvement
of 14.2% for the V30 of PTV30, and the use of MCO for VMAT
optimization led to a net gain of 4.8%. For the ten patients with
metastatic disease, MCO-VMAT provided higher D95 and D99 for
PTV37.5, with the results being statistically signiﬁcant for D95 dif-
ference between MCO-IMRT and STD-VMAT.
Figure 1 compares the coronal view of the isodose distribution
provided by the three modalities for the patient that MCO-VMAT
demonstrated most improvement on V30 of PTV30 (patient 3 in
Table 1). For this patient, only 43.5% of the PTV30 was covered by
the prescription dose in MCO-IMRT, and 82.5% in STD-VMAT. The
use of MCO-VMAT promoted the coverage to 95.4%, which is gen-
erally considered clinically desirable.
Figures 2 and 3 show the dosimetric performance of the three
modalities for the patient with the maximum number of metastatic
lesions (12 for patient 6 as shown in Table 1). Figure 2 shows the D99
of GTV37.5 and D95 for PTV37.5. In general, the three modalities
provided similar target coverage considering the challenges of multiple
lesions. Figure 3 compares the dose volume histogram (DVH) for vari-
ous target volumes and normal organs. Both MCO- and STD-VMAT
created lower hotspots in the whole brain and spared more hippocam-
pus than MCO-IMRT. MCO-VMAT and MCO-IMRT led to lower dose
to the lens. MCO-VMAT signiﬁcantly reduced the dose to the com-
bined cochleas compared to the other two modalities. Overall, MCO-
VMAT offered the best combination of target coverage and normal
tissue sparing for this most challenging case.
3.C | Treatment plan quality parameters
On average, MCO-VMAT resulted in a lower overall plan Dmax hot-
spot. The decrease was 1.2 Gy and 1.8 Gy when compared to
MCO-IMRT (P = 0.047) or STD-VMAT (P < 0.01), respectively. Dose
TAB L E 1 Comparison of plan performance for the ten SIB HA-WBRT patients. MV stands for MCO-VMAT, MI for MCO-IMRT, and SV for
STD-VMAT.
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uniformity, quantiﬁed by the volume receiving 35 Gy with the
PTV30 but outside PTV37.5, observed MCO-VMAT (2.7%), when
compared to MCO-IMRT (3.1%) or STD-VMAT (2.3%). A signiﬁcant
decrease was observed for the average monitor unit (MU) for MCO-
VMAT (746.9), when compared to MCO-IMRT (1191.8) or STD-
VMAT (1152.3). The reduction was 37% and 35%, respectively
(P < 0.01 for both.)
4 | DISCUSSION
All MCO-VMAT plans (with or without the SIB to the metastatic
lesions) achieved the RTOG 0933 guidelines (which only required
WBRT to 30 Gy) with acceptable or better hippocampus sparing.26
Prior studies have highlighted MCO for its operational ﬂexibility and
planning efﬁciency, along with superior dosimetric performance.21,24
TAB L E 2 Cumulative average and standard deviation of the plan metrics shown in Table 1, for each treatment modality. The impact of using
VMAT over IMRT in MCO planning is shown under the MCO column, whereas the impact of using MCO over standard optimization in VMAT
planning is shown in the column of VMAT. The differences with statistical signiﬁcance (P < 0.05) is shown in red.
MCO-VMAT MCO-IMRT STD-VMAT
F I G . 1 . Isodose plan comparison in the
coronal view for the patient that MCO-
VMAT demonstrated most improvement
on the coverage of the whole brain PTV30
(patient 3 in Table 1).
F I G . 2 . Comparison of target coverage provided by MCO-VMAT, MCO-IMRT and STD-VMAT, for the patient with 12 metastatic lesions
(patient 6). The results are shown for the (a) D99 of the metastatic GTV (GTV37.5) and (b) D95 of the metastatic PTV (PTV37.5) that receive
the SIB. The target volumes are shown beside the charts.
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With the navigation function in MCO, metrics such as dose unifor-
mity and maximum dose can be loosened for the potential of greater
OAR sparing or more target coverage. In this HA-WBRT study, the
constraints were customized based on the hippocampus volume, the
number, size and location of any metastatic lesions, to allow the gen-
eration of the Pareto surface from a favorable starting position. As
reported in prior studies, if the navigation is done in a very unbal-
anced manner or pushed towards extreme values, dose discrepancy
will appear at the MLC segmentation stage when the optimizer tries
to ﬁnd the MLC pattern physically allowed by the linear accelerator
that can mimic the ﬂuence map achieved at the end of the naviga-
tion step.21 The discrepancy is also attributed to the difference in
dose calculation algorithm — pencil beam in Pareto optimization and
the more accurate collapsed cone in ﬁnal dose calculation after the
MLC segmentation. The possibility of real-time navigation using a
spectrum of Pareto-optimal plans can lower the learning curve for
planning staff and thus encourage more clinics to consider highly
conformal treatment (e.g., SIB with VMAT) in very complex anatomi-
cal situations (e.g., hippocampal sparing, limbic circuit sparing).7,27
Prokic et al. reported that the SIB technique could achieve better
hippocampal sparing compared to sequential boost in form of stereo-
tactic radiation therapy (e.g., 8 Gy 9 2) after WBRT.28 In addition,
the use of a single isocenter for the treatment of multiple brain
metastasis led to reduced delivery time while maintaining the
dosimetry quality, as compared to the sequential boost.29 Our study
demonstrates that MCO-VMAT allows for hippocampal sparing
despite a variety of SIB conditions (number of lesions, size of targets
and proximity to hippocampus). Also, the SIB approach allowed
selective dose escalation for lesions within less than 5 mm to the
hippocampus which would otherwise be rejected for protocol. As
reported by Gondi et al., 3% of brain metastases in 8.6% of patients
were found within 5 mm of the hippocampus (n = 371). 30 In our
study, MCO-VMAT achieved dose escalation to 37.5 Gy for lesions
as close as 1.3 mm from the hippocampus (patient 5). This example
shows the potential tradeoffs between target coverage and OAR
sparing, as controlling metastatic burden is also a key factor in neu-
rocognitive outcomes.31 In this case, both MCO modalities increased
PTV 37.5 SIB target coverage for the tumor in close proximity to
the hippocampus. However, MCO-VMAT offered 95% coverage for
PTV30, whereas MCO-IMRT and STD-VMAT only provided 83%
and 86%, respectively, with comparable hippocampus metrics as
shown in Table 1. MCO allowed user ﬂexibility for clinicians to prior-
itize high-risk target clinical objectives utilizing Pareto optimal navi-
gational solutions. Thus, SIB with MCO-VMAT may allow for
meaningful hippocampal sparing for patients who would otherwise
not be eligible due to peri-hippocampal metastases.
5 | CONCLUSION
MCO-VMAT was proven superior to MCO-IMRT or STD-VMAT for
HA-WBRT. This study sampled patients with various numbers of meta-
static lesions (0 to 12), and the lesions had a wide variety of size and
location with respect to the hippocampus. On average, MCO-VMAT
improved the PTV30 coverage, with statistical signiﬁcance, by 14.2%
and 4.8%, respectively, compared to MCO-IMRT and STD-VMAT. It
also slightly boosted the dose to GTV37.5 and PTV37.5. Finally, MCO-
VMAT signiﬁcantly reduced theMUs, resulting in faster treatment com-
pared to bothMCO-IMRT and STD-VMAT.
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